InfuSystem Holdings, Inc. (INFU) 股票分析

公司概述

InfuSystem Holdings, Inc. operates primarily within the United States and Canada, delivering a specialized portfolio of infusion pumps and associated consumable products through its subsidiaries. The company functions within the Healthcare sector, specifically targeting the Medical Devices industry, where it serves critical needs in patient care and clinical administration. Its operational scale is defined by a market capitalization of $195.63M and an annual revenue of $143.44M, supported by a workforce of 461 employees. These valuation and revenue figures position the firm as a mid-cap entity with a tangible asset base focused on electronic ambulatory infusion pumps, indicating a specialized niche rather than broad market dominance. The distinction between its two segments, Patient Services and Device Solutions, underscores a diversified approach to revenue generation within the infusion therapy space.

财务健康

The company reported a trailing twelve-month revenue of $143.44M and a net income of $6.63M, resulting in an EBITDA of $24.11M. The significant disparity between the revenue figure and the net income highlights a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 95.4% of total revenue before arriving at the final profit. Free cash flow stands at $14.83M, which provides the organization with substantial financial flexibility to fund capital expenditures, service its debt obligations, or potentially pursue strategic acquisitions without immediate reliance on external financing. Profitability efficiency is further illuminated by three key margins: a Gross Margin of 56.0%, an Operating Margin of 4.7%, and a Profit Margin of 4.6%, indicating that while the core product manufacturing is highly efficient, operating leverage is constrained by high overheads. On the liability side, the company holds $3.19M in cash against $24.44M in total debt, creating a debt-to-equity ratio of 42.63, which suggests a leveraged balance sheet where equity is used to support a significant debt load. Liquidity risk is mitigated by a Current Ratio of 1.80, confirming that current assets are nearly double current liabilities and providing a comfortable buffer for short-term obligations. Return metrics reveal a Return on Equity of 11.5% and a Return on Assets of 6.7%, indicating that management is effectively deploying shareholder capital to generate returns, though the ROA remains lower due to the asset-heavy nature of the medical device industry.

估值评估

Valuation metrics indicate a trailing P/E ratio of 31.03 and a forward P/E of 33.17, suggesting that the market anticipates earnings growth that will be slower than the current earnings base, as the forward multiple is higher than the trailing multiple. The Price to Book ratio stands at 3.39, implying that the stock trades at a significant premium over its book value, reflecting investor confidence in the company's intangible assets and future cash flow generation capabilities beyond its tangible net worth. Alternative valuation measures include a Price to Sales ratio of 1.36 and an EV/EBITDA of 8.95, which provide context for the stock's valuation relative to its sales volume and operating earnings, respectively. Regarding price volatility, the stock has a 52-week high of $11.04 and a 52-week low of $4.66, meaning the current market price sits within a range that reflects significant historical fluctuation. The Beta value of 1.55 indicates that the stock exhibits higher price volatility than the broader market, moving approximately 1.5 times as much as the general market index during periods of fluctuation.

Growth & Income

Growth dynamics are characterized by a Revenue Growth (YoY) of 7.0% and an Earnings Growth (YoY) of 123.9%, demonstrating that earnings are expanding at a pace significantly faster than revenue. This divergence implies that the company is achieving substantial margin expansion or one-time gains that are boosting profitability disproportionately to top-line sales growth. As the company does not currently pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it retains all earnings to reinvest into research and development, manufacturing capacity, or market expansion strategies. Consequently, the overall profile of InfuSystem Holdings, Inc. is one of aggressive earnings expansion funded by retained earnings rather than shareholder distributions, typical for growth-oriented medical device manufacturers in the early to mid-stage of their development cycles.